PDL BioPharma (PDLI:NAS) and Sierra Oncology (SRRA:NAS) Trading at Less than Cash Value

Stockcalc – Free Trial

Have a free look inside the StockCalc website at www.stockcalc.com

I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/TopPicks.aspx.

Trading at Less than Cash Value

Today we are looking at companies trading at less than cash value meaning companies whose current share price is less than the cash per share on the balance sheet. We also show the value of cash net debt per share to show how much cash per share would be left if the debt was paid off.

What this Means…

Companies can have more cash per share than the actual share price for a number of reasons including they just raised capital, are in industries that experience high burn rates and will eat through the cash quickly or if there is a lot of uncertainty about the future of the company. Companies earning a positive net income will have a P/E greater than 0 and are worth exploring in more detail.

Today’s Data on NASDAQ

Today’s data is for companies listed on the NASDAQ.

Symbol Name Close Price Shares Outstanding P/E P/B Cash per Share Net Cash per Share
LEXEB Liberty Expedia Holdings Inc 48.050000 57276969 None 1.0939 55.75 -28.30
LEXEA Liberty Expedia Holdings Inc 44.100000 57276969 None 1.0039 55.75 -28.30
SOHU Sohu.com Ltd 17.080000 38916788 None 1.0005 29.71 23.98
PDLI PDL BioPharma Inc 2.610000 145400381 3.6029 0.5325 2.72 1.89
SRRA Sierra Oncology Inc 1.680000 74344181 None 1.0352 1.69 0.32
SCPH scPharmaceuticals Inc 5.150000 18569289 None 1.0795 5.43 4.91
NLNK NewLink Genetics Corp 2.360000 37214286 None 0.7029 3.68 3.68
OPHT Ophthotech Corp 2.410000 36198436 0.5657 4.9765 4.03 5.82
ACET Aceto Corp 2.250000 30787241 None 0.7270 3.28 -7.03
AQXP Aquinox Pharmaceuticals Inc 2.740000 23537368 None 0.7112 4.21 4.21
VBLT Vascular Biogenics Ltd 1.620000 35855461 None 0.9513 1.63 1.03
VVUS VIVUS Inc 4.335000 10622716 None None 5.38 -22.43
NVLN Novelion Therapeutics Inc 1.880000 18852557 None None 2.12 -13.42
APWC Asia Pacific Wire & Cable Corp Ltd 2.450100 13819669 8.4486 0.2140 3.91 1.37
GIGM GigaMedia Ltd 2.850000 11052235 32.0000 0.5290 5.50 5.77
GEMP Gemphire Therapeutics Inc 1.900000 14265411 None 1.8012 1.97 1.25
ASNS Arsanis Inc 1.840000 14315410 None 0.6975 3.49 2.71
CYCC Cyclacel Pharmaceuticals Inc 1.430000 11997447 None 0.9212 1.65 0.96
NVIV InVivo Therapeutics Holdings Corp 2.040000 7763420 None 1.8562 2.88 2.83
ABAC Renmin Tianli Group Inc 1.950000 7983745 24.3750 0.1747 7.87 7.61
ACHV Achieve Life Sciences Inc 2.590000 4551005 0.0174 0.7169 3.36 0.92
RTTR Ritter Pharmaceuticals Inc 2.120000 5534639 None 1.0992 2.94 None
ATOS Atossa Genetics Inc 1.660000 5500000 None 0.6730 2.77 1.43
KBSF KBS Fashion Group Ltd 3.820000 2206741 None 0.1170 10.93 10.21
RLM Realm Therapeutics PLC 2.790000 4662476 None 0.5357 3.48 2.74

Let’s look at a few companies…

Lets look at a couple of the companies on this list to get a better understanding of them.


PDL BioPharma has 87 employees and is headquartered in United States.
PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing value of its patent.

SRRA:NAS Sierra Oncology

Sierra Oncology has 57 employees and is headquartered in Canada.
Sierra Oncology Inc is a clinical-stage drug development company engaged in next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer.

Free Valuation

Run a valuation on any of the companies listed above at www.stockcalc.com/valureport.aspx or subscribe at our Stockcalc Facebook Page to receive this list each day Stockcalc Reports.

The content presented here is in part from the website stockcalc.com and is provided on an as is or as available basis with all faults and may not be current in all cases. You should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment decision.